Historically, the most promising success stories in the characterisation and treatment of these comparably clear-cut monogenetic conditions such as SMA and CLN2 disease have only prevailed following decades of challenges building on an initial characterisation of the causative gene or mutation. Here, TPP1 is linked to proximal spinal muscular atrophy.